Half-yearly Report

Eco Animal Health Group Plc

ECO Animal Health Group plc (â€˜â€™ECOâ€)

(AIM: EAH)

Results for the six months ended 30 September 2015

ECO ANIMAL HEALTH REPORTS STRONG PERFORMANCE

HIGHLIGHTS

Financials

27% increase in revenue to Â£21.5 million (2014:Â£17.0 million), equivalent to a 28% increase at constant exchange rates (CER)
26% increase in adjusted EBITDA to Â£4.3 million (2014: Â£3.4 million), equivalent to a 36% increase at CER
33% increase in pre-tax profit to Â£2.7 million (2014: Â£2.0 million)
31% increase in earnings per share to 3.52 pence (2014:2.68 pence)
17% increase in gross profit to Â£8.9 million (2014: Â£7.6 million)
27% increase in interim dividend to 1.9 pence (2014:1.5 pence)
Cash generation again strong leaving net cash of Â£17.0 million (2014: Â£14.3 million)

Operations

Demand for Aivlosin^Â® continues to grow strongly with sales up over 32%, equivalent to 34% at CER
Strong performances in all major territories
EU approval of Maximum Residue Level for poultry eggs allowed submission of applications for new marketing authorisations
Continued investment in stockholding achieved and production capacity increase on schedule

Peter Lawrence, Executive Chairman of ECO Animal Health Group plc, commented:

"The second half of the year has started well continuing the momentum of the first six months. ECO is in excellent financial and commercial health and we look forward with confidence to delivering another strong set of results, backed by further penetration of key markets and the achievement of additional marketing authorisations."

Contacts:

ECO Animal Health Group plc	Â	Â	Â		Â	Â
Peter Lawrence				020 8336 6190
Marc Loomes				020 8447 6906
							Â
Spiro Financial
Anthony Spiro				020 8336 6196
							Â
Peel Hunt LLP (Nominated Adviser)
Dan Webster, Richard Brown, George Sellar				020 7418 8900

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Chairmanâ€™s Statement

I am delighted to report that ECO Animal Health has delivered another strong performance in the six months to 30 September 2015. This advance has continued the good performance achieved in the last financial year which was driven by further growth in North America, China and Europe, and boosted by the acquisition of distribution rights in Southeast Asia reported last year. It is extremely encouraging that the company has built on these successes in the period under review. These results have been achieved despite the ongoing relative strength of sterling against the majority of currencies in which we trade.

ECO operates in a market segment that provides essential medications to the global animal protein production industry which seeks to meet the ever growing demand from a world prospering from technological and social progress.

Financial performance

Sales rose by 27% to Â£21.5m (2014: Â£17.0m), while EBITDA (earnings before interest, tax, depreciation, amortisation, share based payments and foreign exchange movements) increased by 26% to Â£4.3m (2014: Â£3.4m), equivalent to 36% at constant exchange rates (CER). The balance sheet retains its strength and Group cash at the period end was Â£17.0m (2014: Â£14.3m). The Group cash balance stated after investing Â£2.4 million in planned increases in strategic stock levels. Pre-tax profit rose by over 33% to Â£2.7m (2014: Â£2.0m), while earnings per share were ahead by 31% at 3.52 pence (2014: 2.68 pence). The board is pleased to increase the interim dividend by 27% to 1.9 pence per share (2014: 1.5 pence). The dividend will be paid on April 4^th 2016 to shareholders on the register on 11 March 2016.

Operations

ECO Animal Health Groupâ€™s global sales grew by 28% at constant exchange rates (CER). Sales generated in all regions were ahead of the comparable period last year. Worldwide sales of AivlosinÂ®, our patented molecule for the treatment of economically important diseases of pigs and poultry, increased by 32% (over 34% at CER). AivlosinÂ® is prescribed under strict veterinary control at low but efficacious dose rates for short duration treatments of specified diseases and meets all the US Food & Drug Administration (FDA) guidelines for the responsible use of antimicrobials, which when used appropriately help ensure animal welfare and food safety.

ECOâ€™s major regions achieved strong double digit AivlosinÂ® sales growth, the exceptions being the smaller markets in the Middle East and Africa, where sales declined modestly.

In China, our subsidiary, Zhejiang ECO Biok Animal Health Products, which was established over ten years ago, had another very successful trading period with sales rising 25 % in sterling.

Sales of AivlosinÂ® in North America increased by over 16% in sterling compared with the same period last year. This excellent result was achieved in a period of unusually mild weather and with the disease pressure considered by experts to be at its lowest for many years. We are well positioned to build on our excellent start as we wait for additional marketing authorisations to be granted in this important market.

In Japan, one of our most mature markets, total sales rose 22% in sterling (33% in yen) reflecting the benefits of a strategic business review and the development of closer ties with key customers.

In Brazil, sales were ahead by close to 75% in sterling (135% in local currency) as a result of winning several key tenders and an improved performance from non-tender business. In other parts of Latin America, the uncertain economic and political situation in Argentina, Mexico and Venezuela impacted our business although overall, the region reported good growth.

In July 2014 we acquired the business of our long-standing Southeast Asian distributor based in Kuala Lumpur, with representation throughout the region. This region has performed extremely well with sales up almost 60% in sterling. Following a strategic review of the opportunities offered by these important pig and poultry markets, the company has now established a representative office in the region and has begun to recruit locally.

Sales in Europe, including the UK, were ahead in the period, maintaining the positive momentum established last year, although the economic climate in the region remains challenging.

The company has continued to invest in its research and product development programme with the intention of obtaining additional marketing authorisations in the key pig and poultry production markets globally. Our announcement in September concerning the establishment of the official maximum residue level for AivlosinÂ® for poultry eggs received from the Committee for Medicinal Products for Veterinary Use at the European Medicines Agency is another example of our progress towards making the company a truly major force in worldwide animal health.

Outlook

The second half of the year has started well continuing the momentum of the first six months.

ECO is in excellent financial and commercial health and we look forward with confidence to delivering another strong set of results, backed by further penetration of key markets and the achievement of additional marketing authorisations.

Peter A Lawrence
4 December 2015

CONSOLIDATED INCOME STATEMENT
FOR THE SIX MONTHS TO 30 SEPTEMBER 2015

Six months

Year

ended

30.09.15

30.09.14

31.03.15

Notes

(unaudited)

(audited)

Â£000

Revenue

21,499

16,959

38,997

Cost of sales

(12,552)

(9,333)

(21,546)

Gross Profit

8,947

7,626

17,451

Other operating income

118

138

293

Administrative expenses

(4,921)

(4,435)

(9,402)

Currency (losses)/profits

(67)

146

Amortisation of intangible assets

(1,339)

(1,236)

(2,794)

Share based payments

(120)

(162)

(252)

Profit from operating activities:

2,618

2,077

5,337

Net finance income/(expense)

(57)

(259)

Profit before income tax

2,694

2,020

5,078

Income tax (charge)

(315)

(199)

(457)

Profit for the period from continuing operations

2,379

1,821

4,621

Attributable to:

Owners

2,158

1,606

4,094

Minority interest

221

215

527

2,379

1,821

4,621

BASIC EARNINGS PER SHARE

3.52p

2.68p

6.82p

FULLY DILUTED EARNINGS PER SHARE

3.47p

2.66p

6.79p

Earnings from continuing activities before

interest, taxation, depreciation, amortisation

and share based payments

4,214

3,554

8,610

Exclude foreign exchange differences

(146)

(41)

EBITDA

4,281

3,408

8,569

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE SIX MONTHS TO 30 SEPTEMBER 2015

Six months

Year

ended

30.09.15

30.09.14

31.03.15

(unaudited)

(audited)

Â£000

Profit for the period

2,379

1,821

4,621

Foreign currency translation differences

(699)

350

Defined benefit pension plan - actuarial gains

(55)

Revaluation of investment property

Other comprehensive income for the period

(699)

330

Total comprehensive income for the period

1,680

1,857

4,951

Attributable to:

Owners

1,674

1,579

4,090

Minority interest

278

861

1,680

1,857

4,951

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SIX MONTHS TO 30 SEPTEMBER 2015

Other

Revaluation

Treasury

Retained

Total

Minority

Total

Capital

Premium

Reserves

Reserve

Earnings

Interest

Equity

Account

Â£000

At 1 April 2014

3,124

53,429

1,816

533

(5,217)

16,955

70,640

2,168

72,808

Total comprehensive income for the period:

Profit for the year

4,094

527

4,621

Other comprehensive income

Revaluation of investment property

Deferred taxation movements

(9)

Foreign currency translation differences

334

350

Actuarial (losses) on pension scheme assets

(55)

Total comprehensive income for the period

4,055

4,090

861

4,951

Transactions with owners

Issue of shares in the year

769

802

Purchase of shares into treasury

(17)

Dividends

(2,515)

Share based payments

252

Transfer to retained earnings on option expiry

(293)

293

Total transactions with owners

769

(41)

(2,239)

(1,478)

At 31 March 2015

3,157

54,198

1,775

568

(5,217)

18,771

73,252

3,029

76,281

Total comprehensive income for the period:

Profit for the period

2,158

221

2,379

Other comprehensive income

Foreign currency translation differences

(484)

(215)

(699)

Total comprehensive income for the period

1,674

1,680

Transactions with owners

Issue of shares in the year

1,054

1,091

Repayment of loan from Employee Benefit Trust

2,315

Purchase of shares into treasury

(43)

Share based payments

120

Transfer to retained earnings on option expiry

(69)

Dividends

(1,059)

(402)

(1,461)

Total transactions with owners

1,054

2,315

(1,033)

2,424

(402)

2,022

At 30 September 2015

3,194

55,252

1,826

568

(2,902)

19,412

77,350

2,633

79,983

Prior interim period

At 1 April 2014

3,124

53,429

1,816

533

(5,217)

16,955

70,640

2,168

72,808

Total comprehensive income for the period:

Profit for the period

1,606

215

1,821

Other comprehensive income

Foreign currency translation differences

(27)

Total comprehensive income for the period

1,579

278

1,857

Transactions with owners

Share based payments

162

Transfer to retained earnings on option expiry

(38)

Dividends

(2,515)

Total transactions with owners

124

(2,477)

(2,353)

At 30 September 2014

3,124

53,429

1,940

533

(5,217)

16,057

69,866

2,446

72,312

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Â	Â	Â		Â	Â	Â	As at	Â	Â	Â	As at	Â	Â	Â	As at	Â	Â
								30.09.15				30.09.14				31.03.15
								(unaudited)				(unaudited)				(audited)
																			Â
				Notes				Â£000				Â£000				Â£000
																			Â
ASSETS
Non current assets
Goodwill and other intangibles				8				47,211				45,043				45,660
Property,plant and equipment				9				1,722				1,072				1,619
Investment property				10				187				147				189
Investments								9	Â	Â	Â	9	Â	Â	Â	9
								49,129				46,271				47,477
																			Â
Current assets
Inventories								11,905				9,536				9,833
Trade and other receivables								11,814				9,407				11,522
Income tax recoverable								10				46				39
Other taxes and social security								364				477				110
Cash and cash equivalents								16,960	Â	Â	Â	17,521	Â	Â	Â	20,091
								41,053				36,987				41,595
								Â	Â	Â	Â	Â	Â	Â	Â	Â
Total assets								90,182	Â	Â	Â	83,258	Â	Â	Â	89,072
																			Â
Current liabilities
Trade and other payables								(9,362)				(7,125)				(9,542)
Short term borrowings								-				(3,229)				(2,356)
Income tax								(219)				(119)				(223)
Other taxes and social security								(299)				(268)				(343)
Dividends								(36)	Â	Â	Â	(37)	Â	Â	Â	(35)
								(9,916)				(10,778)				(12,499)
																			Â
Total assets less current liabilities								80,266				72,480				76,573
																			Â
Non current liabilities
Deferred tax								(183)				(168)				(192)
Dilapidations on property leases								(100)	Â	Â	Â	-	Â	Â	Â	(100)
								79,983	Â	Â	Â	72,312	Â	Â	Â	76,281
Equity
Capital and reserves
Called up share capital								3,194				3,124				3,157
Share premium								55,252				53,429				54,198
Treasury reserve								(2,902)				(5,217)				(5,217)
Revaluation reserve								568				533				568
Other reserves								1,826				1,940				1,775
Retained earnings								19,412	Â	Â	Â	16,057	Â	Â	Â	18,771
								77,350				69,866				73,252
Minority interest								2,633	Â	Â	Â	2,446	Â	Â	Â	3,029
Total equity								79,983	Â	Â	Â	72,312	Â	Â	Â	76,281

CONSOLIDATED STATEMENT OF CASHFLOWS

Six months to

Year ended

30.09.15

30.09.14

31.03.15

(unaudited)

(audited)

Â£000

Cashflows from operating activities

Profit before tax

2,694

2,020

5,078

Adjustment for:

Net finance costs

(76)

259

Depreciation of property plant and equipment

140

186

(Gains)/losses on disposal of non-current assets

(2)

Amortisation of intangible assets

1,339

1,236

2,538

Impairment of intangible assets

256

Pension payments

(59)

Pension operating costs

Share based payments

120

162

252

Operating cash flow before movement in working
capital

4,215

3,554

8,555

Change in inventories

(2,072)

(2,564)

(2,861)

Change in receivables

(546)

289

(1,460)

Change in payables

(224)

872

3,463

Cash generated from operations

1,373

2,151

7,697

Interest (paid)

(5)

(1)

(31)

Income tax (paid)

(299)

(314)

(446)

Net cash inflow from operating activities

1,069

1,836

7,220

Cash flows from investing activities

Purchase of property plant and equipment

(295)

(179)

(778)

Sale of motor vehicle

Costs of acquiring drug registrations and distribution
rights

(2,890)

(3,107)

(5,280)

Purchase of own shares

(43)

(17)

Interest received

Net cash (used in) investing activities

(3,190)

(3,247)

(5,998)

Cash flows from financing activities

Proceeds from issue of share capital

3,406

802

Dividends paid

(1,461)

(2,509)

(2,510)

Net cash from/(used in) financing activities

1,945

(2,509)

(1,708)

Net (decrease)/increase in cash and cash
equivalents

(176)

(3,920)

(486)

Foreign exchange movements

(599)

(28)

(19)

Cash and cash equivalents at the beginning of the
period

17,735

18,240

Cash and cash equivalents at the end of the period

16,960

14,292

17,735

NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2015

1. Basis of preparation

The financial information for the period to 30 September 2015 does not constitute statutory accounts as defined by Section 435 of the Companies Act 2006. It has been prepared in accordance with the accounting policies set out in, and is consistent with, the audited financial statements for the twelve months to 31 March 2015.

The Group applies revised IAS 1 â€œPresentation of Financial Statements (2007)â€, which became effective as of 1 January 2009. As a result, the Group presents all non-owner changes in equity in consolidated statements of comprehensive income and all owner changes in equity in consolidated statements of changes in equity.

2. Statement of compliance

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all of the disclosure requirements in IAS 34 â€œInterim Financial Reportingâ€. Accordingly, whilst the interim statements have been prepared in accordance with IFRS, they cannot be construed as being in full compliance with IFRS and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 March 2015.

3. Revenue is derived from the Groupâ€™s animal pharmaceutical businesses.

4. Principal risks and uncertainties

These were set out on pages 58-60 of the notes to the consolidated financial statements for the year ended 31 March 2015. The key exposures are to foreign currency exchange rates, potential delays in obtaining marketing authorisations and single sources of supply for some raw materials and have remained unchanged since the year end.

5. Earnings per share

	Â	Â	Â	Six months to	Â	Â	Â	Six months to	Â	Â	Â	Year ended	Â	Â
				30.09.15				30.09.14				31.03.15
				(unaudited)				(unaudited)				(audited)
															Â
															Â
Weighted average number of shares in issue (000's)				61,307				59,871				60,007
Fully diluted weighted average number of shares in issue (000's)				62,087				60,312				60,289
															Â
Profit attributable to equity holders of the company (Â£'s)				2,158				1,606				4,094
															Â
Basic earnings per share (pence)				3.52				2.68				6.82
Fully diluted earnings per share (pence)				3.47				2.66				6.79

6. Dividends

Six months to

Year ended

30.09.15

30.09.14

31.03.15

(unaudited)

(audited)

Â£000

Dividend in respect of the year ended 31 March 2014

62,474,231 shares at 4.2p per share.

2,624

Dividend in respect of the year ended 31 March 2014

63,134,343 shares at 1.75p per share

1,105

Dividend waived by employee benefit trust

(46)

(109)

Dividend paid by subsidiary to non-controlling interests

(minorities)

402

1,461

2,515

The Company paid a further dividend of 3 pence per share on 2^nd October 2015, after the period end.

The total paid after allowing for the dividend waived by the Employee Benefit Trust was Â£1.88 million.

7. Related party transactions

At the balance sheet date, ECO Animal Health Group plc owed P A Lawrence, a director of ECO Animal Health Group plc, and members of his family a balance amounting to Â£297,368 (30 September 2014: Â£133,843).

During the period the Group provided management services to C-Corp Limited, a company in which P A Lawrence is a director and holds equity interests. Fees charged were: Â£21,643 (2014: Â£21,663).

During the period the Group made sales to Zhejiang ECO Biok Animal Health Products Limited at an armâ€™s length basis to the value of Â£1,143,425 (Six months to 30 September 2014: Â£2,913,590). At the end of this period there was an intercompany balance owing from this company of Â£464,109 (30 September 2014: Â£1,093,822).

The Group also made sales on an armâ€™s length basis to ECO Animal Health do Brasil Comercio de Productos Veterinarios Ltda to the value of Â£2,422,591 (Six months to 30 September 2014 Â£1,584,059). At the end of the period there was an intercompany balance of Â£440,345 (30 September 2014: Â£551,596).

The Group also made sales on an armâ€™s length basis to ECO Animal Health Japan Inc to the value of Â£494,849 (30 September 2014: Â£161,065). At the end of the period there was an intercompany balance of Â£298,098 (30 September 2014: Â£84,191).

The Group also made sales on an armâ€™s length basis to ECO Animal Health de Mexico to the value of Â£88,124 (Six months to September 2014: 62,941). At the end of the period there was an inter-company balance of Â£590,130 (30 September 2013: Â£814,965).

The Group also made sales on an armâ€™s length basis to ECO Animal Health USA Corp to the value of Â£1,821,017 (six months to 30 September 2014: 1,396,259). At the end of the period there was an inter-company balance of Â£2,055,451 (30 September 2014: Â£1,024,205).

The Group also made sales on an armâ€™s length basis to Pharmgate Animal Health Canada Inc to the value of Â£892,620 (six months to September 2014: Â£889,821). At the end of the period there was an inter-company balance of Â£174,544 (30 September 2014: Â£354,769).

All of the transactions have been eliminated on consolidation, as well as the whole of the balances relating to the subsidiaries and the groupâ€™s share of the balances relating to the US and Canadian joint ventures. During the period ECO Animal Health Ltd and ECO Animal Health Group plc received a dividend of Â£418,550 (2014: Â£nil) from Zhejiang ECO Biok Animal Health Products Limited.

8. Intangible non-current assets

Distribution

Development

Goodwill

Rights

Costs

Total

Cost

Â£000

Cost at 1 April 2014

17,930

1,266

48,252

67,448

Additions

176

2,931

3,107

Cost at 30 September 2014

17,930

1,442

51,183

70,555

Additions

2,173

Cost at 31 March 2015

17,930

1,442

53,356

72,728

Additions

2,890

Cost at 30 September 2015

17,930

1,442

56,246

75,618

Amortisation

Amortisation at 1 April 2014

544

23,732

24,276

Charge for the period

1,201

1,236

Amortisation at 30 September 2014

579

24,933

25,512

Charge for the period

1,266

1,302

Impairment for the year

256

Foreign exchange movements

(2)

Amortisation at 31 March 2015

615

26,453

27,068

Charge for the period

1,303

1,339

Amortisation at 30 September 2015

651

27,756

28,407

Net book value at 30 September 2015

17,930

791

28,490

47,211

Net book value at 1 April 2015

17,930

827

26,903

45,660

Net book value at 30 September 2014

17,930

863

26,250

45,043

Net book value at 1 April 2014

17,930

722

24,520

43,172

9. Property, plant and equipment

	Â	Â	Â		Â	Â	Â		Â	Â	Â	Fixtures,	Â	Â	Â		Â	Â	Â		Â	Â
				Freehold				Plant and				fittings &				Motor
				Property				Machinery				equipment				Vehicles				Total
Cost				Â£000				Â£000				Â£000				Â£000				Â£000
Cost at 1 April 2014				650				1,205				473				76				2,404
Additions				-				58				93				27				178
Disposals				-	Â	Â	Â	-	Â	Â	Â	-	Â	Â	Â	(11)	Â	Â	Â	(11)
Cost at 30 September 2014				650				1,263				566				92				2,571
Additions				-				535				65				-				600
Disposals				-				(524)				-				-				(524)
Foreign exchange movements				-	Â	Â	Â	153	Â	Â	Â	-	Â	Â	Â	(6)	Â	Â	Â	147
Cost at 1 April 2015				650				1,427				631				86				2,794
Additions				-				257				38				-				295
Disposals				-				-				-				(31)				(31)
Foreign exchange movements				-	Â	Â	Â	(61)	Â	Â	Â	(6)	Â	Â	Â	-	Â	Â	Â	(67)
Cost at 30 September 2015				650	Â	Â	Â	1,623	Â	Â	Â	663	Â	Â	Â	55	Â	Â	Â	2,991
																							Â
Depreciation
Depreciation at 1 April 2014				9				934				402				57				1,402
Charge for the period				5				52				18				9				84
Disposals				-				-				-				(11)				(11)
Foreign exchange movements				-	Â	Â	Â	24	Â	Â	Â	-	Â	Â	Â	-	Â	Â	Â	24
Depreciation at 30 September 2014				14				1,010				420				55				1,499
Charge for the period				4				65				21				9				99
Disposals				-				(474)				-				-				(474)
Foreign exchange movements				-	Â	Â	Â	52	Â	Â	Â	1	Â	Â	Â	(2)	Â	Â	Â	51
Depreciation at 1 April 2015				18				653				442				62				1,175
Charge for the period				5				87				40				6				138
Disposals				-				-				-				(31)				(31)
Foreign exchange movements				-	Â	Â	Â	(13)	Â	Â	Â	-	Â	Â	Â	-	Â	Â	Â	(13)
Depreciation at 30 September 2015				23	Â	Â	Â	727	Â	Â	Â	482	Â	Â	Â	37	Â	Â	Â	1,269
																							Â
Net book value
Net book value at 30 September 2015				627	Â	Â	Â	896	Â	Â	Â	181	Â	Â	Â	18	Â	Â	Â	1,722
																							Â
Net book value at 1 April 2015				632	Â	Â	Â	774	Â	Â	Â	189	Â	Â	Â	24	Â	Â	Â	1,619
																							Â
Net book value at 30 September 2014				636	Â	Â	Â	253	Â	Â	Â	146	Â	Â	Â	37	Â	Â	Â	1,072
																							Â
Net book value at 1 April 2014				641	Â	Â	Â	271	Â	Â	Â	71	Â	Â	Â	19	Â	Â	Â	1,002

10 Investment property

	Â	Â	Â	Freehold	Â	Â	Â		Â	Â
				Property				Total
Cost				Â£000				Â£000
											Â
Cost at 1 April 2014 and 30 September 2014				157				157
											Â
Revaluation at 31 March 2015				32				32
				Â	Â	Â	Â	Â
Valuation at 31 March 15 and 30 September 2015				189	Â	Â	Â	189
											Â
											Â
Depreciation
Depreciation at 1 April 2014				8				8
Charge for the period ended 30 September 2014				2				2
				Â	Â	Â	Â	Â
Depreciation at 30 September 2014				10				10
Charge for the period ended 31 March 2015				1				1
Elimination on revaluation 31 March 2015				(11)	Â	Â	Â	(11)
Depreciation at 31 March 2015				-				-
Charge for the period ended 30 September 2015				2				2
				Â	Â	Â	Â	Â
Depreciation at 30 September 2015				2	Â	Â	Â	2
											Â
Net book value
Net book value at 30 September 2015				187	Â	Â	Â	187
Net book value at 31 March 2015				189	Â	Â	Â	189
Net book value at 30 September 2014				147	Â	Â	Â	147
Net book value at 1 April 2014				149	Â	Â	Â	149

This financial information was approved by the board on 04 December 2015.

Copies of this interim report are being sent to all of the Companyâ€™s shareholders. Further copies can be obtained from the Companyâ€™s registered office at 78 Coombe Road, New Malden, Surrey KT3 4QS.

DIRECTORS AND OFFICERS	Â	Â	Â	Peter Lawrence	Â	Â	Â	(Chairman)	Â	Â
				Marc Loomes				(Chief Executive)
				Kevin Stockdale				(Finance Director)
				Julia Trouse				(Executive Director and Company secretary)
				Brett Clemo				(Executive Director)
				David Danson				(Non-Executive Director)
				Anthony Rawlinson				(Non-Executive Director)
											Â
REGISTERED OFFICE				78 Coombe Road, New Malden, Surrey. KT3 4QS
				Tel: 020-8336-2900				Fax: 020-8336-0909
											Â
COMPANY NUMBER				01818170
INFORMATION AT				www.ecoanimalhealthgroupplc.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20151206005014/en/

Companies

ECO Animal Health Group (EAH)

Wednesday, 22nd January 2025

COMPANIES COVERED:

EZJ HOC QLT

Quilter gains on strong inflows, but easyJet loses ground despite improved pre-Christmas trade and Hochschild Mining hammered as broker notes overshadow positive production report.

Full Archive

UK 100

Latest directors dealings

1 hour ago Polar Capital Holdings
1 hour ago LondonMetric Property
2 hours ago Liontrust Asset Management
2 hours ago Liontrust Asset Management
2 hours ago Mineral & Financial Investments Limited (DI)

All directors dealings today